Plasma membrane lipid interface (PMLI)

The plasma membrane lipid interface refers to the complex boundary region of the cell where the hydrophilic lipid headgroups interact with the aqueous environment and the hydrophobic tails form the bilayer core. This interface is not merely a passive barrier but a dynamic platform that regulates the localization and activity of numerous peripheral and integral membrane proteins involved in vital signaling cascades. By influencing membrane physical properties such as lateral pressure, fluidity, and the formation of microdomains like lipid rafts, the interface plays a crucial role in cellular homeostasis and communication. In various pathologies, including cancer and neurodegenerative diseases, the composition and organization of these lipid interfaces are often altered, leading to dysfunctional signaling. Therapeutic strategies known as membrane lipid therapy (melitherapy) aim to pharmacologically modulate these lipid structures to restore normal protein function or selectively destroy pathogenic cells, such as bacteria or fungi, by compromising their membrane integrity. Drugs like 2-hydroxyoleic acid and various polyene antifungals exemplify the clinical application of targeting the lipid interface to treat complex human diseases.

Other names

Lipid bilayer interfaceMembrane-water interfacePlasma membrane lipidsMembrane lipid bilayerLipid-protein interface

Drugs targeting the plasma membrane lipid interface typically act by altering the physical properties of the membrane, such as fluidity, thickness, or curvature, which in turn modulates the activity of membrane-bound signaling proteins. Some agents, like certain antibiotics and antifungals, work through pore formation or direct disruption of the lipid bilayer integrity, leading to cell death. Others, used in membrane lipid therapy (melitherapy), specifically reorganize lipid domains (e.g., lipid rafts) to correct aberrant signaling pathways in diseases like cancer or diabetes.